Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Magnesium in Cisplatin HIOCC
NCT04481672Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magnesium sulfate in acute kidney injury (AKI), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Feasibility and acceptability at 6 months and Number of Participants With Treatment-Related Adverse Events at 2 days. Started Jul 2021; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04481672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481672.